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ABSTRACT
Allelic deletions on the short arm of chromosome 6 (6p) are one of the
common, possibly early, genetic changes that occur in the pathogenesis of
cervical carcinoma (CC). Previous loss of heterozygosity (LOH) studies in
CC identified a number of critical regions of deletions on 6p. However, the
precise location of minimally deleted regions and their role in precancer-
ous lesions have not been well characterized. To address these questions,
we first performed a detailed LOH analysis on 6p in 59 cases of invasive
CC. The pattern of LOH identified two minimal regions of deletions, one
spanning a 5 cM genetic distance at 6p25 and a second site of 10.3 cM
deletion mapping to 6p21.3. The 6p21.3 minimal deletion spans HLA class
I genes. To understand the role of 6p genetic alterations in the develop-
ment of CC, we also investigated 12 high-grade and 4 low-grade cases of
cervical intraepithelial neoplasia (CIN) for LOH after laser microdissec-
tion. The high-grade CINs exhibited 91.7% LOH, and low-grade CINs
had 50% LOH. These findings implicate the presence of at least two tumor
suppressor genes on 6p relevant to CC and suggest that these genetic
alterations occur very early in CC development. This study should there-
fore facilitate the identification of tumor suppressor genes on 6p and may
identify which CINs are at high risk of progressing to invasive CC.
INTRODUCTION
The short arm of chromosome 6 (6p) is frequently affected by
LOH5 in a high proportion of CCs (1–5), suggesting the presence of
one or more TSGs on this chromosomal arm. Previous allelotype
studies have indicated potential sites of TSGs at 6p23 (6), and at
6p21.3 (5, 7, 8) in CC. The latter region of deletion spans the HLA
class I antigen genes, thus suggesting a potential role for HLA genes
in the development of CC. These studies have also indicated for a
third candidate TSG site of deletion at subtelomeric loci on 6p, but the
boundaries of the deletion have not been identified (7, 8). Although
these data provide strong evidence for the presence of TSGs on 6p that
may be relevant to CC, the critical regions of loss on 6p have not been
identified precisely.
To identify the critical regions of LOH, we performed a detailed
deletion mapping on 6p in invasive CC and identified two regions of
minimal deletions at 6p25 and 6p21.3 spanning a 5 cM and a 10.3 cM
genetic distance, respectively. We have also found that these genetic
alterations occur in CIN, suggesting that they represent genetic
changes that occur early in the process of cervical tumorigenesis.
MATERIALS AND METHODS
Tumor/Normal Tissues. A total of 75 tumor biopsies representing 59
frozen, previously untreated, primary invasive CCs with corresponding periph-
eral blood samples and 16 formalin-fixed, paraffin-embedded specimens from
low-grade (CINI) and high-grade (CINII, CINIII/carcinoma in situ) CINs
comprised the material. The tissues were obtained from patients treated at the
Instituto Nacional de Cancerologia (Santa Fe de Bogota´, Colombia) after
appropriate informed consent and approval of the protocol by the institutional
review board. Clinically, the tumors were classified as follows: (a) FIGO stage
1B, 4 tumors; (b) FIGO stage IIB, 15 tumors; (c) FIGO stage IIIB, 36 tumors;
and (d) FIGO stage IV, 4 tumors. Histologically, 56 tumors were classified as
squamous cell carcinomas, and 3 tumors were classified as adenocarcinomas.
The samples from CINs included 12 high-grade and 4 low-grade lesions.
Laser Microdissection, DNA Isolation, and LOH Analysis. High molec-
ular weight DNA from frozen tumor and peripheral blood specimens was
isolated as described previously (9). Tumor cells from paraffin-embedded CIN
tissue specimens were isolated by laser capture microdissection (Arcturus,
Mountain View, CA) after methyl green staining, and DNA was extracted by
digestion with proteinase K for 72 h. Twenty-three STRP (20 dinucleotide and
3 tetranucleotide) markers were chosen on the basis of their map position and
heterozygosity (Table 1; Gene Map 99).6 A standard PCR reaction containing
[g-32P]dATP end-labeled forward primer, analysis of PCR products on dena-
turing polyacrylamide sequencing gels, and scoring of LOH on autoradiograms
were performed as described previously (9). The criteria used for scoring LOH
were described previously (10). All autoradiograms were independently scored
visually by three investigators (A. C., H. A. P., and V. V. V. S. M.). The def-
inition of the minimal region of deletion was based on LOH of the loci that
span common deletions in several tumors and retention of heterozygosity of
adjoining markers at both the boundaries in at least two tumors. The LOH
analysis was performed at least twice on all tumors with the corresponding
markers that define minimal deletion.
RESULTS
Analysis of LOH in Invasive CC Identifies Two Common Re-
gions of Deletions at 6p25 and 6p21.3. Evaluation of LOH on a
panel of 59 invasive CCs with 23 STRP markers mapped to chromo-
some 6p revealed deletions in at least one marker in 66.1% (39 cases)
of the tumors. Of the 39 tumors that had LOH on 6p, 8 (21%) showed
LOH at all of the informative markers, suggesting 6p monosomy. The
patterns of LOH in the remaining 31 tumors that exhibited regional
losses on 6p were used to identify minimal regions of deletion (Table
1; Fig. 1). This LOH pattern in invasive CCs revealed two common
regions of minimal deletions at 6p25 and 6p21.3 (Fig. 1).
The 6p25 minimal region of deletion derived from 20 tumors
spanned the marker AFMB034Ya5 flanked by marker D6S344 prox-
imally and D6S1617 distally. The deletion boundaries were defined
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by tumors T-86, T-118, and T-55 proximally and tumors T-6 and T-55
distally (Fig. 1). The 6p21.3 minimal deletion was deduced from the
pattern of LOH in 24 tumors as shown in Fig. 1 and Fig. 3. This
deletion was spanned by the STRP markers D6S422, D6S1691, and
D6S265 flanked by markers CHLC.GATA87C11 proximally and
MOG(CA)n distally. The 6p21.3 deletion boundaries were defined by
tumors T-2 and T-13 proximally, and tumors T-13 and T-55, distally.
All but 1 of the 39 tumors with 6p deletions fell within the two
defined regions of minimal deletions. Twenty-two tumors exhibited
LOH at both regions, whereas 6 tumors showed deletions only at
6p25, and 10 others had deletions only at 6p21.3. Thus, we identified
two discrete sites of minimal deletions in CC at 6p25, which was
restricted to a 5 cM genetic distance, and 6p21.3, which spans a 10.3
cM genetic distance.
Identification of LOH at 6p25 and 6p21.3 in Precancerous and
Early Cancerous Lesions. To evaluate LOH in early cervical can-
cerous lesions, we studied 16 microdissected CIN specimens using 7
STRP markers spanning 6p25 and 6p21.3, the regions that exhibited
a high frequency of LOH in invasive CCs. The pattern of LOH in
high-grade and low-grade CINs is shown in Fig. 2.
Eleven of 12 (91.7%) high-grade CINs had LOH at one or more
informative markers. Five of these lesions had LOH at all markers
studied on 6p, and four others showed deletions encompassing both
the 6p25 and 6p21.3 regions but retained heterozygosity of proximal
markers. The remaining two high-grade CINs exhibited LOH only at
the 6p23–25 region and retained constitutional heterozygosity at all
proximal markers including the 6p21.3 region.
Of the four low-grade CINs studied, two (50%) exhibited LOH, one
each at the 6p23–25 and 6p21.3 regions (Fig. 2 and Fig. 3). Thus,
deletions at 6p25 and 6p21.3 were found in both high- and low-grade
CINs, suggesting that these genetic alterations represent very early
change in the development of CC.
DISCUSSION
The high frequency of LOH on 6p in CC suggests the possible
existence of critical genes in tumor suppression (4, 5, 7, 8). However,
the locations of the exact regions of LOH are not known due to lack
of systematic LOH mapping studies, except for a single report by
Rader et al. (6) identifying a minimal deletion at the 6p23 region. In
the present study, we performed high-density LOH mapping on 6p
and identified two minimal regions of deletions at 6p25 and 6p21.3.
The 6p25 deletion exhibited LOH in 74% (28 of 39 tumors) of the
cases, and the 6p21.3 minimal deletion exhibited LOH in 87% (32 of
39 tumors) of the cases among the specimens that had 6p deletions.
The 6p25 minimal deletion that spans a 5 cM genetic distance is a
novel site that has not been described previously. Although the 6p25
region has been shown to have a high frequency of LOH in several
previous studies (4, 5, 7, 8), the exact location of the minimal deletion
is not known. Rader et al. (6) restricted the deletion at 6p23 to a 1 cM
distance between 26–27 cM genetic distance. In contrast, our analysis
identified the minimal deletion between 1.0 and 6.4 cM genetic
distance, (Fig. 1), which is 20 cM distal to the one reported by Rader
et al. (6). In the present study, despite the fact that we found a high
frequency of LOH at markers spanning the 6p23 region, the patterns
of LOH identified the minimal deletion at 6p25. Consistent with this
observation, marker AFMb34ya5 mapping to the 6p25 region exhib-
ited the highest frequency (70.4%) of LOH among all of the tested loci
(Table 1). The discrepancy between our study and that of Rader et al.
(6) may be due to differences in the number and density of markers
used in the region or may represent two separate targets of deletions.
The 6p25 minimal deletion interval contains at least 9 genes, 17
UniGenes, and 5 expressed sequence tags.7 The genes include PECI,
PRP4, TUBB, PI6, ELANH2, NMOR2, BPHL, FKHL6, and FKHL7.
The biological functions of theTUBB, PI6, ELANH2, FKHL6, and
FKHL7 genes suggest a putative TSG role for these genes. The TUBB
b-tubulin gene is a member of tubulin multigene family that forms
microtubules, which is a constituent of the eukaryotic cytoskeleton
and mitotic apparatus. The b-tubulin gene modulates drug responses
in human cancer cells by binding to the b-tubulin component of
a-/b-tubulin heterodimers that facilitate blocking cells at G2-M phase
and lead to cell death. Mutations and differential expression of iso-
types in the b-tubulin gene confer acquired resistance to anticancer
drug taxanes in cancer (11, 12). We have performed mutation analysis
of the coding region of the TUBB gene by single-strand conforma-
tional polymorphism in 30 invasive CCs that exhibited 6p LOH,
followed by direct sequencing of PCR products of tumors suspected
of conformational variations by single-strand conformational poly-
morphism (data not shown). No pathogenic mutations were identified
by this analysis, suggesting that TUBB is not a target TSG of the
deletion at 6p25 in CCs.
The PI6 and ELANH2 genes belong to a superfamily of serine
protease inhibitors that play a role in many cellular processes includ-
ing matrix remodeling and apoptosis. A member of this family, the
PI5 (maspin) gene, has been shown previously to have a tumor
suppressor role in breast carcinoma (13). The FKHL6 and FKHL7
genes belong to a large family of forkhead (Drosophila) genes that
regulate transcription. Mutations in forkhead genes cause develop-
mental anomalies (14). The presence of these genes in the 6p25
deletion interval suggests that they may be the targets of deletion in
CC and may function as cervical cancer TSGs.
The second site of minimal deletion at 6p21.3 identified in the
present study has also been reported to have frequent LOH in invasive
CC (4, 7, 8). Although the precise location of the minimal deletion
was unclear, the HLA class I genes have been shown to be part of the
6p21.3 deletion interval. In the present study, we identified a 10.3-cM
minimal deletion between 34.0 and 44.3 cM genetic distance (Fig. 1).
This 6p21.3 deletion interval is highly gene rich because the region
harbors at least 64 genes, 67 UniGene clusters, and 30 expressed
sequence tags.7 The genes in the 6p21.3 deletion interval include
clusters of 12 histone family genes, 5 butyrophilin family genes, 8
7 http://www.ncbi.nlm.nih.gov/genemap/map.cgi?CHR56.









6p25 D6S1600 0.0 56/47 20 (42.6)
D6S344 1.0 57/48 26 (54.2)
AFMbO34ya5 1.4 57/27 19 (70.4)
D6S1617 6.4 59/47 26 (55.3)
D6S1640 11.4 59/43 20 (46.5)
6p24 CHLC.GATA23E10 14.0 57/37 9 (24.3)
6p22–23 D6S1267 25.9 59/44 22 (50.0)
D6S260 29.6 58/51 26 (51.0)
D6S469 29.6 58/39 19 (48.7)
D6S1584 32.4 53/41 19 (46.3)
CHLC.GATA87C11 34.0 58/40 21 (52.5)
6p22.1 D6S422 35.7 59/41 22 (53.7)
6p21.3 D6S1691 42.7 56/42 24 (57.1)
D6S265 44.3 59/43 22 (51.2)
6p21.1–21.3 MOG (CA)n 44.5 57/49 24 (49.0)
D6S273 44.9 59/42 23 (54.8)
D6S276 44.9 59/41 19 (46.3)
TAP1 (CA)n 45.4 59/44 19 (43.2)
D6S291 49.6 58/37 17 (45.9)
6p11.2–12 D6S1549 62.3 59/41 15 (36.6)
D6S1650 68.7 57/47 18 (38.3)
6p11.1 D6S272 74.1 58/49 15 (30.6)
6p10 D6S1681 85.0 57/46 10 (21.7)
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ZNF proteins, 5 HLA class I genes, and 4 KIAA gene products.
Histones are the basic nuclear proteins responsible for the nucleosome
structure of the chromosomal fiber in eukaryotes involved in the
formation of higher order structures of chromatin (15). They contrib-
ute to virtually all chromosomal processes, such as gene regulation,
chromosome condensation, recombination, and replication. Buty-
rophilin genes belong to the immunoglobulin superfamily that plays a
role in the development of mammary epithelial cells during lactation
(16). A large number of the ZNF family proteins exist in human
genome. The ZNF genes perform many key functions, the most
important of which is regulation of transcription. The ZNF domains
are also thought to be involved in both normal and abnormal cellular
proliferation and differentiation (see OMIM number 603971). HLA
class I molecules regulate immune response by ligand binding to the
T-cell receptor on cytotoxic T cells that recognize and destroy tumor
cells. Genetic changes at the 6p21.3 region containing HLA class I
molecules may affect the expression of these genes and therefore may
allow tumor cells to evade the immune response. Among the other
genes mapped to the 6p21.3 deletion interval, the human immediate
early response 3 (IER3) gene contains binding sites for transcription
factor p53, NF-kB, CEBP, and SP1 genes and thus may have a role in
cell growth regulation (17, 18). Mutation analysis of the coding region
of the IER3 gene in 30 cases of invasive CC that exhibited 6p LOH
did not reveal any pathogenic alterations (data not shown).
Although the role of these gene(s) or gene clusters in cervical
carcinogenesis remains unknown, the HLA class I genes have been
proposed as targets of 6p21.3 deletions in CC. Loss of HLA class I
antigen gene expression is a common phenomenon in most CCs (19),
and the loss of HLA-A2 and B7 expression is associated with a poor
prognosis in CC (20). The underlying mechanism for the loss of HLA
class I gene expression in CC has recently been shown to be genetic
alterations including LOH at 6p21.3 and mutations in the HLA-A
and/or HLA-B alleles (21). Koopman et al. (21) found that 70% of
CCs with loss of HLA class I expression harbor multiple genetic
Fig. 1. Patterns of LOH on 6p in invasive CC. Thirty tumors that exhibited partial deletions are represented here. A G-banded ideogram of chromosome 6 is shown on top. Thick
horizontal lines shown below the G-banded ideogram represent 6p chromosomal regions. STRP markers are shown by small vertical lines on the thick horizontal lines. Genetic map
positions are shown below the thick horizontal line. Each tumor is represented by a horizontal line; marker/region of LOH is shown by light shading, and retention of heterozygosity
is shown by dark shading. Tumor numbers are shown on the right or left of the horizontal lines. Shaded tumor numbers indicate a common deletion at both the 6p25 and 6p21.3 regions.
For convenience of presentation, 6p25 and 6p21.3 regions of deletions are presented separately. Thick black rectangles at the bottom indicate regions of minimal deletion.
Fig. 2. LOH on 6p in high- and low-grade cervical CINs. Twelve high-grade CINs and
four low-grade CINs are represented. A G-banded ideogram is shown on the left, and the
corresponding polymorphic loci are shown to the right of the ideogram. Patterns of
deletions are indicated by circles below the CIN numbers corresponding to each marker.
F, LOH; hatched circle, retention of heterozygosity; E, homozygous and uninformative;
circle containing ND, not done. Two large rectangles represent regions corresponding to
6p23–25 and 6p21.3.
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alterations, including 50% of the cases with LOH on 6p. Our present
definition of 6p21.3 minimal deletion includes several HLA class I
genes (HLA-A, P5–1, HLA-C, HLA-Bw72, MICA, and HLA-E) at the
proximal boundary, supporting the observations made by Koopman et
al. (21). Our data therefore suggest that the loss of expression of HLA
class I genes seen in many CCs may be due to targeted deletions at
6p21.3. Furthermore, 6p21 LOH has been reported to be predictive of
disease recurrence after radiotherapy in CC (22). It remains to be seen
whether any TSGs exist at the 6p21.3 minimal deletion and whether
there is any synergy between the TSG and MHC class I genes in CC
development.
Our study identified two discrete sites of deletions at 6p25 and
6p23.1 that harbor candidate gene(s) important in CC development.
This provides a basis for further investigations in finding TSGs in
these deleted targets. The 6p genetic deletions have also been reported
in CINs, which are precursor lesions for invasive CCs (5, 23). These
data therefore suggest that the 6p genetic alterations occur early in
cervical carcinogenesis and that they may be critical to the develop-
ment of this tumor. In the present study, we detected LOH at 6p25 and
6p21.3 in 91.7% of high-grade CINs and 50% of low-grade CINs,
respectively (Fig. 2), supporting previous reports that these alterations
are very early events in cervical carcinogenesis (5, 23). The 6p genetic
alterations documented here in low-grade CINs and high-grade CINs
have two potential implications. First, our data should facilitate un-
covering the target genes of importance, which may provide a better
understanding of the genetic basis of cervical carcinogenesis. Second,
because only a certain fraction of precancerous lesions has the poten-
tial to progress to invasive cancer (24), the markers and/or regions
deleted in CIN lesions may facilitate the identification of high-risk
dysplasias. The present study thus provides a basis for the identifica-
tion of TSGs on 6p involved in CC and for the analysis of a large
cohort of precancerous lesions to validate the usefulness of the deleted
markers in identification of high-risk dysplasias.
ACKNOWLEDGMENTS
We thank the gynecologists at Instituto Nacional de Cancerologı´a for
specimen collection. We also thank Dr. Ralph Richart for reviewing the
histopathological material and critical reading of the manuscript.
REFERENCES
1. Mitra, A. B., Murty, V. V. V. S., Li, R. G., Pratap, M., Luthra, U. K., and Chaganti,
R. S. K. Allelotype analysis of cervical carcinoma. Cancer Res., 54: 4481–4487,
1994.
2. Rader, J. S., Kamarosova, T., Huettner, P. C., Li, L., Li, Y., and Gerhard, D. S.
Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene, 13:
2737–2741, 1996.
3. Mullokandov, M. R., Kholodilov, N. G., Atkin, N. B., Burk, R. D., Johnson, A. B.,
and Klinger, H. P. Genomic alterations in cervical carcinoma: losses of chromosome
heterozygosity and human papilloma virus tumor status. Cancer Res., 56: 197–205,
1996.
4. Huettner, P. C., Gerhard, D. S., Li, L., Gersell, D. J., Dunnigan, K., Kamarasova, T.,
and Rader, J. S. Loss of heterozygosity in clinical stage IB cervical carcinoma:
relationship with clinical and histopathologic features. Hum. Pathol., 29: 364–370,
1998.
5. Karsemaekers, A. M., van de Vijver, M. J., Kenter, G. G., and Fleuren, G. J. Genetic
alterations during the progression of squamous cell carcinomas of the uterine cervix.
Genes Chromosomes Cancer, 26: 346–354, 1999.
6. Rader, J. S., Li, Y., Huettner, P. C., Xu, Z., and Gerhard, D. S. Cervical cancer
suppressor gene is within 1 cM on 6p23. Genes Chromosomes Cancer, 27: 373–379,
2000.
7. Mazurenko, N., Attaleb, M., Gritsko, T., Semjonova, L., Pavlova, L., Sakharova, O.,
and Kisseljov, F. High resolution mapping of chromosome 6 deletions in cervical
cancer. Oncol. Rep., 6: 859–863, 1999.
8. Krul, E. J., Kersemaekers, A. M., Zomerdijk-Nooyen, Y. A., Cornelisse, C. J., Peters,
L. A., and Fleuren, G. J. Different profiles of allelic losses in cervical carcinoma cases
in Surinam and The Netherlands. Cancer (Phila.), 86: 997–1004, 1999.
9. Pulido, H. A., Fakruddin, M. J., Chatterjee, A., Esplin, E. D., Belen˜o, N., Martı´nez,
G., Posso, H., Evans, G. A., and Murty, V. V. V. S. Identification of a 6 cM minimal
deletion at 11q23.1–23.2 and exclusion of PPP2R1B gene as a deletion target in
cervical cancer. Cancer Res., 60: 6677–6682, 2000.
10. Mitra, A. B., Murty, V. V. V. S., Singh, V., Li, R. G., Pratap, M., Sodhani, P., Luthra,
U. K., and Chaganti, R. S. K. Genetic alterations at 5p15: a potential marker for
progression of precancerous lesions of the uterine cervix. J. Natl. Cancer Inst.
(Bethesda), 87: 742–745, 1995.
11. Giannakakou, P., Poy, G., Zhan, Z., Knutsen, T., Blagosklonny, M. V., and Fojo, T.
Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with
tubulin mutations in human cancer. Oncogene, 19: 3078–3085, 2000.
12. Montgomery, R. B., Guzman, J., O’Rourke, D. M., and Stahl, W. L. Expression of
oncogenic epidermal growth factor receptor family kinases induces paclitaxel resist-
ance and alters b-tubulin isotype expression. J. Biol. Chem., 275: 17358–17363,
2000.
13. Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A., Neveu, M., Sheng, S., Rafidi, K.,
Seftor, E., and Sager, R. Maspin, a serpin with tumor-suppressing activity in human
mammary epithelial cells. Science (Washington DC), 63: 526–529, 1994.
14. Pierrou, S., Hellqvist, M., Samuelsson, L., Enerback, S., and Carlsson, P. Cloning and
characterization of seven human forkhead proteins: binding site specificity and DNA
bending. EMBO J., 13: 5002–5012, 1994.
15. Smith, M. M. Histone structure and function. Curr. Opin. Cell Biol., 3: 429–437,
1991.
Fig. 3. Illustration of LOH at 6p25 and 6p21.3 common regions of deletions in invasive cervical cancer and precancerous lesions. A, the 6p25 region of deletions in invasive cancer
is represented by two tumors, T-55 and T-115. Tumor T-55 shows LOH of 6p25 marker AFMB034yA5 but retains heterozygosity of both proximal and distal markers. T-115 shows
LOH of all markers except the proximal GATA23E10 marker. B, the 6p21.3 region of deletions is represented by two tumors, T-55 and T-117. Tumor T-55 shows LOH of marker
D6S265 but retains heterozygosity of both proximal and distal markers. T-117 shows LOH of markers GATA87C11 and D6S291 but retains heterozygosity of both proximal and distal
markers. C, LOH in low-grade CINs. Case C-16 shows LOH at the 6p23–25 region (D6S1617 and D6S1267), whereas the proximal marker (MOG) mapped to 6p21.3 is heterozygous.
Case C-20 shows LOH at 6p21.3 (MOG) but retains heterozygosity at 6p25 (D6S1617). N, normal; T, tumor; C, CIN. Asterisks indicate LOH. Tumor numbers are shown at the top
of each panel, and markers are indicated on the sides of the panels.
2122
IDENTIFICATION OF TUMOR SUPPRESSOR SITES AT 6p
16. Tazi-Ahnini, R., Henry, J., Offer, C., Bouissou-Bouchouata, C., Mather, I. H., and
Pontarotti, P. Cloning, localization, and structure of new members of the butyrophilin
gene family in the juxta-telomeric region of the major histocompatibility complex.
Immunogenetics, 47: 55–63, 1997.
17. Wu, M. X., Ao, Z., Prasad, K. V. S., Wu, R., and Schlossman, S. F. IEX-1L, an
apoptosis inhibitor involved in NF-kB-mediated cell survival. Science (Washington
DC), 281: 998–1001, 1998.
18. Schmidt, W. E., Arlt, A., Trauzold, A., and Schafer, H. p22/PRG1: a novel early
response gene in pancreatic cancer cells regulated by p53 and NF kB. Ann. N. Y.
Acad. Sci., 880: 147–156, 1999.
19. Keating, P. J., Cromme, F. V., Duggan-Keen, M., Snijders, P. J., Walboomers, J. M.,
Hunter, R. D., Dyer, P. A., and Stern, P. L. Frequency of down-regulation of
individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expres-
sion. Br. J. Cancer, 72: 405–411, 1995.
20. van Driel, W. J., Tjiong, M. Y., Hilders, C. G., Trimbos, B. J., and Fleuren, G. J.
Association of allele-specific HLA expression and histopathologic progression of
cervical carcinoma. Gynecol. Oncol., 62: 33–41, 1996.
21. Koopman, L. A., Corver, W. E., van der Slik, A. R., Giphart, M. J., and Fleuren, G. J.
Multiple genetic alterations cause frequent and heterogeneous human histocompatibility
leukocyte antigen class I loss in cervical cancer. J. Exp. Med., 191: 961–976, 2000.
22. Harima, Y., Harima, K., Sawada, S., Tanaka, Y., Arita, S., and Ohnishi, T. Loss of
heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after
radiotherapy of human cervical cancer. Clin. Cancer Res., 6: 1079–1085, 2000.
23. Rader, J. S., Gerhard, D. S., O’Sullivan, M. J., Li, Y., Li, L., Liapis, H., and Huettner,
P. C. Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p.
Genes Chromosomes Cancer, 22: 57–65, 1998.
24. Zur Hausen, H., and Rosl, F. Pathogenesis of cancer of the cervix. Cold Spring Harbor
Symp. Quant. Biol., 9: 623–628, 1994.
2123
IDENTIFICATION OF TUMOR SUPPRESSOR SITES AT 6p
